ANI Pharmaceuticals (ANIP) announced the launch of Nitazoxanide Tablets, 500 mg. ANI’s Nitazoxanide Tablets are the generic version of the reference listed drug, or RLD, Alinia. U.S. annual sales for Nitazoxanide Tablets total approximately $36.1M, based on December 2024 moving annual total IQVIA data.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals announces royalty obligation buyout for Iluvien, Yutiq
- Positive Outlook for ANI Pharmaceuticals: FDA Approval and Strategic Moves Drive Buy Rating
- ANI Pharmaceuticals announces FDA approval for expansion of Iluvien label
- ANI Pharmaceuticals initiated with a Buy at Jefferies
- ANI Pharmaceuticals initiated with an Overweight at JPMorgan